Relmada Therapeutics, Inc. (RLMD) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Next earnings call: 2026-08-06
(Q2 2026)
— full calendar
Earnings Reports
-
Realmada Therapeutics (RLMD) Q1 2026: $160M Capital Infusion Extends Runway for Phase III NMIBC Program
June 17, 2026
-
Roll Mata Therapeutics (RLMD) Q2 2025: NDV-01 Achieves 91% Response Rate, Expands Bladder Cancer Opportunity
June 16, 2026
-
Ramada Therapeutics (RLMD) Q3 2025: $100M Raise Extends Runway, NDV-01 Phase 3 Set for 2026
June 16, 2026
-
Relmada Therapeutics (RLMD) Q4 2025: $160M Financing Extends Runway Through 2029 as NDVO1 Phase III Nears
June 16, 2026
-
RealMata (RLMD) Q1 2025: Cash Burn Rises 39% as NDVO1 and Cepranolone Advance Toward Next Milestones
May 12, 2025